

UNCLASSIFIED

AD NUMBER
ADB259834
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Sep 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 8 Jan 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8062

TITLE: Interindividual Difference in Metabolism of Carcinogens as
a Risk Factor for Breast Cancer

PRINCIPAL INVESTIGATOR: Regine Goth-Goldstein, Ph.D.

CONTRACTING ORGANIZATION: University of California at Berkeley
Berkeley, California 94720

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Sep 99). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20001121 081

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.


LIMITED RIGHTS LEGEND


Award Number: DAMD17-98-1-8062

Organization: University of California at Berkeley

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.





REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual (17 Aug 98 - 16 Aug 99)		
4. TITLE AND SUBTITLE Interindividual Difference in Metabolism of Carcinogens as a Risk Factor for Breast Cancer		5. FUNDING NUMBERS DAMD17-98-1-8062		
6. AUTHOR(S) Regine Goth-Goldstein, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California at Berkeley Berkeley, California 94720 E-MAIL: R_Goth-Goldstein@lbl.gov		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Sep 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The proposed study seeks to address the interaction of environmental and genetic factors in the etiology of breast cancer. Cytochrome P450 isozyme (CYP1B1) metabolizes environmental and endogenously formed carcinogens in the breast. We are testing the hypothesis that individuals with higher levels of CYP1B1 are at a higher risk for breast cancer because they produce higher amounts of ultimate carcinogen. The expression level of <i>CYP1B1</i> is being determined in a collection of normal breast tissue samples from reduction mammoplasties and from mastectomy patients and <i>CYP1B1</i> expression is compared in specimen from cancer patients and healthy controls to establish if breast cancer patients have an increased level of the enzyme. During the last year a previously developed assay that uses reverse transcription (RT)-PCR to quantitate expression relative to the β -actin gene, was optimized for quantitation of CYP1B1. <i>CYP1B1</i> and in parallel <i>CYP1A1</i> expression was determined in 30 specimen. CYP1B1 transcript levels ranged from 1.5 to 99. CYP1A1 levels had an even larger interindividual range. In most specimen <i>CYP1B1</i> expression was 2-6 fold that of <i>CYP1A1</i> . <i>CYP1B1</i> expression was significantly higher in the breast cancer group than in the healthy control group.				
14. SUBJECT TERMS Breast Cancer, CYP1B1, CYP1A1, RT-PCR, polycyclic aromatic hydrocarbons, polymorphism			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46. Rgg

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Regine Goth-Goldstein 9/16/99
PI + Signature Date

Table of Contents

SF298	2
Foreword	3
Table of Contents	4
Introduction	5
Body of Annual Report	5
Key Research Accomplishments	9
Reportable Outcomes	9
Conclusions	9
References	10

Interindividual Differences in Metabolism of Carcinogens as a Risk Factor for Breast Cancer

Introduction

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous in the environment from incomplete combustion of fossil fuels and other industrial sources. Coal tars and chimney soot, complex mixtures containing PAHs, were among the first substances ever to be associated with the development of tumors in exposed humans and animals. The major pathway by which ingested or inhaled PAHs are metabolized, is the stepwise oxidative activation by the cytochrome P450 isozymes, CYP1A1 and CYP1B1, followed by detoxification by phase II enzymes (1). The highly reactive intermediate formed by CYP1A1 or CYP1B1 can bind to DNA, the resulting DNA adduct can cause a mutation that if in a relevant gene could initiate cancer. Expression of both *CYP1A1* and *CYP1B1* is highly inducible by PAHs and other environmental toxins, such as dioxin (2).

Whereas CYP1A1 has been studied extensively for over 25 years, much less is known about CYP1B1, one of the newest members of the P450 family. There is considerable evidence that CYP1B1 could be a key enzyme in the activation of carcinogens in the breast and therefore play a role in the development of breast cancer. The *CYP1B1* gene is highly expressed in human breast tissue, but not in liver which has been considered the major site for metabolism of xenobiotic compounds (3). The CYP1B1 enzyme is involved in the activation of a number of lipophilic environmental carcinogens, including PAHs and aromatic amines, and in addition it hydroxylates 17 β -estradiol at the C-4 position to the potentially carcinogenic 4-hydroxy estradiol (4, 5). We are testing the hypothesis that individuals with higher levels of CYP1B1 are at a higher risk for breast cancer because they produce higher amounts of ultimate carcinogen. The expression level of *CYP1B1* is being determined in a collection of normal breast tissue samples from reduction mammoplasties and from mastectomy patients and *CYP1B1* expression is compared in specimen from cancer patients and healthy controls to establish if breast cancer patients have an increased level of the enzyme.

Body of Annual Report

Interindividual variation in carcinogen metabolism has been recognized as an important determinant of susceptibility to various cancers (6,7). The interindividual variability in the level of expression of phase I and phase II enzymes is due in part to genetic polymorphism. Several genetic polymorphisms have been described for CYP1A1 that can affect inducibility (8). Recently two genetic polymorphisms in CYP1B1 have been identified which seem to result in a considerable change of the enzyme activity (9, 10). Besides genetic background, various factors can modify expression of *CYP1A1* and *CYP1B1* in an individual, including hormonal levels, dietary and smoking habits, and exposure to other foreign compounds that act as inducers or repressors.

We are testing the hypothesis that the level of enzymes with the capacity to activate or detoxify environmental carcinogens in the breast represent a risk factor for breast cancer,

and specifically that individuals with higher levels of CYP1B1 are at a higher risk for breast cancer because they produce higher amounts of the ultimate carcinogen. Interindividual variations in the level of *CYP1B1* can be due to either polymorphism in the structural gene, polymorphism in a regulatory gene or finally due to environmental compounds that modify the expression of the enzyme by interacting with the Ah receptor. Since expression is the result of these various factors, studies on genetic polymorphism capture only a fraction of the enzyme variability in at risk individuals. We therefore decided to determine expression of *CYP1B1* in the breast to capture all possible modifying factors. A collection of histologically normal breast tissue specimens from mastectomy patients and from reduction mammoplasties is being analyzed. The goal for the initial 18 months of this project is to compare expression of *CYP1B1* in healthy individuals and breast cancer patients.

1. Method for measuring *CYP1B1* expression

The first task was to set up a quantitative RT-PCR assay for quantitation of CYP1B1 transcript by modifying an assay previously developed in this laboratory for quantitation of CYP1A1 relative to a constantly expressed gene (β -actin). We optimized the PCR reaction conditions to amplify a CYP1B1 fragment using previously published primers (3) and determined the range of linearity for the CYP1B1 amplification reaction. Quantitation by PCR is only accurate when the reaction remains in the exponential phase of product accumulation. Also, for relative comparison of different PCR targets, it is essential that the reaction efficiencies of the two targets is similar. We investigated the possibility of using a multiplex quantitative RT-PCR assay to quantify CYP1A1 and CYP1B1 transcripts simultaneously, but the optimal conditions for each target are so different that the reactions occurred with different and low efficiencies which make a simultaneous quantitation impossible.

We have succeeded in developing an assay that measures CYP1B1 expression in parallel to CYP1A1. The reactions occur in separate tubes which allows for optimal conditions and similar reaction efficiencies for each target. (CYP1A1 reaction uses 50 pmole of each primer and 6 mM MgCl₂ while the CYP1B1 reaction used 40 pmole of each primer and 2 mM MgCl₂. Each reaction takes place for 20 cycles using the same annealing temperature therefore, the reactions may take place in the thermal cycler at the same time.) To test the assay, we purified CYP1A1 and CYP1B1 PCR products, diluted them and mixed them together in known ratios before reamplification. Ratios of 100 to 1, 10 to 1, 5 to 1, 3 to 1, 1 to 1 (and the reverse) were made and then quantified by our assay. Relative signal intensities of CYP1A1 to CYP1B1 were as expected from the known mixtures. This test of the assay shows that there is no preferential amplification of one target over the other and that we can discriminate 3-fold differences in expression.

2. Expression of *CYP1B1* in breast tissue specimens

The second task, to determine the expression of the *CYP1B1* gene by this assay in a collection of normal breast tissue specimens from mastectomy patients and from reduction mammoplasties, has been initiated and the first 30 samples have been tested measuring in parallel *CYP1B1* and *CYP1A1* expression. *CYP1A1* expression had been measured previously in the same samples as part of another study. The repeat measurements gave very similar results (90 % of samples varied by less than a factor of

Table I: Expression of *CYP1B1* and *CYP1A1* in normal breast tissue of breast cancer patients and healthy controls

Tissue Source	CYP1A1/ Actin	CYP1B1/ Actin	CYP1B1/ CYP1A1
Reduction mammoplasties	5.2	3.9	0.8
	4.0	3.7	0.9
	3.8	9.9	2.6
	4.7	15.2	3.2
	5.4	21.9	4.0
	3.4	11.7	3.5
	0.2	8.9	42.0
	6.7	41.1	6.2
	0.18	7.1	40.6
	4.9	23.4	4.8
	31.4	7.1	0.2
	12.8	40.1	3.1
	1.2	12.8	10.5
	4.5	19.8	4.4
	9.4	26.4	2.8
	11.4	9.7	0.9
	6.4	13.1	2.0
	2.0	10.5	5.3
Mastectomies	13.3	58.2	4.4
	66.8	70.7	1.1
	25.0	62.9	2.5
	9.4	30.4	3.2
	5.1	98.6	19.3
	0.2	11.4	47.0
	4.1	27.9	6.8
	0.4	12.4	29.6
	16.2	63.6	3.9
	1.7	1.5	0.9
	2.2	11.5	5.1

2). This confirms that the method provides reliable results. In the specimen analyzed so far *CYP1B1* levels relative to actin ranged from 1.5 - 99 and *CYP1A1* levels ranged from 0.18 - 67. The results summarized in Table I show that *CYP1B1* is expressed at higher level than *CYP1A1* in most samples. For 17 of 29 samples the ratio of *CYP1B1* to *CYP1A1* is between 2 and 7, for 6 samples it is below 2, and for 6 samples it is between 10 and 50. These imbalances will be the subject of future studies. The findings indicate that *CYP1B1* is the primary enzyme for PAH metabolism in the breast and might therefore have a role in PAH-carcinogenesis.

The most exciting conclusion from these results is that more specimen with high *CYP1B1* expression are among the breast cancer patients than among healthy controls. The values were analyzed by Student's t-test. Whereas the difference in *CYP1A1* values between the study groups did not achieve statistical significance ($p = 0.1984$), the difference in *CYP1B1* values between the study groups was statistically significant ($p = 0.0046$). The finding supports our hypothesis, that individuals with higher levels of *CYP1B1* are at a higher risk for breast cancer. The study groups were small and we plan to expand the sample size of both groups in the coming year.

Key Research Accomplishments

1. A method has been developed to measure *CYP1B1* expression in parallel to *CYP1A1* expression.
2. This method was used to determine *CYP1B1* and *CYP1A1* expression in 30 normal breast tissue specimen. The results showed that in most specimen *CYP1B1* was expressed at considerably higher levels than *CYP1A1*, indicating that the *CYP1B1* enzyme is primarily responsible for PAH activation in breast tissue.
3. *CYP1B1* expression is significantly higher in the breast cancer patients than in healthy individuals.

Reportable Outcomes

The findings will be presented at the California Breast Cancer Research Symposium. September 17 - 18, 1999 in Los Angeles as part of an invited talk on 'Metabolism of Environmental Chemicals as Breast Cancer Risk' where I will primarily describe an earlier completed study on *CYP1A1* expression and genotype.

Conclusions

Because of the potential important role of *CYP1B1* in the activation of environmental and endogenous compounds to carcinogenic intermediates, it was hypothesized that high *CYP1B1* expression could represent a risk factor for breast cancer. This is the first study to measure expression of *CYP1B1* in a collection of normal breast tissue from mastectomy patients and from reduction mammoplasties, to estimate the interindividual variation of *CYP1B1* levels and to compare expression in breast cancer patients and healthy individuals. The preliminary results show a large interindividual variation in *CYP1B1* expression and indicate that *CYP1B1* is the predominant PAH-metabolizing enzyme in the breast. Finally, in the as yet small number of specimen analyzed, *CYP1B1* expression was higher in the breast cancer group compared to the control group and the difference was statistically significant.

References

1. Nebert, D.W., and Gonzales, F.J. (1987). P450 genes: structure, evolution, and regulation. *Ann. Rev. Biochem.* 56:945-993.
2. Safe, S.H. (1995) Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. *Pharmac. Ther.* 67:247-281.
3. Larsen, M.C. Angus, W.G., Brake, P.B., Eltom, S.E., Sukow, K.A., and Jefcoate, C.R. (1998) Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. *Cancer Res.* 58:2366-2374.
4. Shimida, T., Hayes, C., Yamazaki, H. Amin, S., Hecht, S.S., Guengrich, P. and Sutter, T. (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. *Cancer Res.* 56 2979-2984.
5. Hayes, C.L., Spink, D.C., Spink, B.C., Cao, J.Q., Walker, N.J. Sutter, T.R. (1996) 17 β -estradiol hydroxylation catalyzed by human cytochrome P4501B1. *Proc. Nat. Aca. Sciences* 93: 9776-9781.
6. Harris, C. (1989). Interindividual variation among humans in carcinogen metabolism DNA adduct formation and DNA repair. *Carcinogenesis* 10:1563-1566.
7. Nebert, D.W. (1996) Role of genetics and drug metabolism in human cancer risk *Mutation Res.* 247: 267-281.
8. Cascorbi, I., Brockmoller, J., Roots, I. (1996) A C4887A polymorphism in exon 7 of human *CYP1A1*: population frequency, mutation linkages, and impact on lung cancer susceptibility. *Cancer Res.* 56: 4965-4969.
9. Bailey, I.R., Roodi, N., Dupont, W.D., Parl, F.F. (1998) Association of cytochrome P4501B1 (*CYP1B1*) polymorphism with steroid receptor status in breast cancer. *Cancer Res.* 56: 5038-5041.
10. Hanna, I.H., Roodi, N., Guengrich, F.P., Parl, F.F. (1999) Pharmacogenetics of human cytochrome P450 1B1. *Proc. Am. Assoc. Cancer Res.* #337.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

8 Jan 2003

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to the enclosed. Request the limited distribution statement for the enclosed be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB265840	ADB266633	ADB282069
ADB279138	ADB251763	ADB265386
ADB264578	ADB281601	ADB282057
ADB281679	ADB258874	ADB258251
ADB281645	ADB281773	ADB264541
ADB261128	ADB281660	ADB241630
ADB261339	ADB259064	ADB281924
ADB273096	ADB266141	ADB281663
ADB281681	ADB281664	ADB281659
ADB259637	ADB258830	
ADB256645	ADB266029	
ADB262441	ADB281668	
ADB281674	ADB259834	
ADB281771	ADB266075	
ADB281612	ADB281661	